Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMO | Q99835 | 4/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.54 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | AR | P10275 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CHKA | P35790 | 2/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1999559 | 0.90 | SMO (0.65) | SMOMEN1KMT2ASLC34A1RECQL | |
| SCHEMBL5206995 | 0.85 | SMO (0.58) | SMOMEN1KMT2ASLC34A1RECQL | |
| SCHEMBL1999531 | 0.80 | RECQL (0.55) | SMOMEN1KMT2ASLC34A1RECQL | |
| SCHEMBL1997979 | 0.78 | SMO (0.60) | SMOLMNADRD2DRD4DRD3 | |
| SCHEMBL9961731 | 0.76 | SMO (0.57) | SMOMEN1KMT2ASLC34A1RECQL | |
| SCHEMBL9961631 | 0.76 | SMO (0.59) | SMOMEN1KMT2ASLC34A1RECQL | |
| Hydrochloric Acid SCHEMBL3327835 | 0.75 | SMO (0.56) | SMOMEN1KMT2ASLC34A1RECQL | |
| Hydrochloric Acid SCHEMBL3321149 | 0.75 | SMO (0.58) | SMOMEN1KMT2ASLC34A1RECQL | |
| SCHEMBL9961699 | 0.74 | SMO (0.57) | SMOMEN1KMT2ASLC34A1RECQL | |
| SCHEMBL2003468 | 0.74 | AR (0.48) | SMOMEN1KMT2ASLC34A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960413-B2 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| EP-1611094-B1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20060276650-A1 | Pyrazole compounds | MERCK PATENT GMBH (DE) | 2006-12-07 | — | — | US | disclosed |
| EP-1611094-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GmbH (DE) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089888-A1 | PYRAZOLE COMPOUNDS | MERCK PATENT GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276650-A1 | Pyrazole compounds | HTR1D, HTR1A, HTR3A | SMO 3168/4885MEN1 2070/4885KMT2A 4173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.